UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: CLBS |
| Industry | Biopharmaceuticals |
| Founded | 2006 (2006) |
| Headquarters | New York City, New York, U.S. |
|
Key people
|
David J. Mazzo (CEO) |
| Website | caladrius.com |
Caladrius Biosciences (NASDAQ: CLBS) is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.
The company was founded in 1980 and was formerly known as Corniche Group Inc, Phase III Medical Inc and NeoStem, Inc. It is headquartered in New York City, New York.
In 2012 they started a phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow derived cell therapy enriched for CD34+ cells, for Acute Myocardial Infarction. Initial results included a statistically significant mortality benefit. After the interim results reported in Nov 2014 the company clarified the changes to the study.
The cancer therapies (Melapuldencel-T and ovapuldencel-T) below are an autologous dendritic cell-based immunotherapy using the patients own dendritic cells and samples of their tumour to make dendritic cells aimed at the patients tumour antigens. This should activate T cells to attack the tumour.
| 2014-11-14 | Resumed | Maxim Group | Buy | $15 |
| 2014-09-18 | Reiterated | WBB Securities | Strong Buy | $27 |
| 2014-01-02 | Reiterated | Aegis Capital | Buy | $21 to $23 |
| 2013-09-12 | Initiated | MLV & Co | Buy | $16 |
| 2013-06-24 | Initiated | Aegis Capital | Buy | $2.50 |
| 2012-07-09 | Upgrade | WBB Securities | Buy to Strong Buy | $2 |
| 2012-01-19 | Upgrade | WBB Securities | Speculative Buy to Buy | $1.85 to $2 |
| 2011-09-16 | Initiated | JMP Securities | Mkt Outperform | $3 |
| 2011-08-16 | Upgrade | WBB Securities | Hold to Speculative Buy | |
| 2010-12-03 | Initiated | Morgan Joseph | Buy | $3.50 |
| 2010-06-29 | Upgrade | WBB Securities | Sell to Hold | $1.85 |
| 2010-06-03 | Initiated | WBB Securities | Sell | $2 |
| 2010-05-27 | Initiated | Maxim Group | Buy | $5 |
| 2010-03-12 | Initiated | Roth Capital | Buy | $2.50 |
| 2014-11-14 | Resumed | Maxim Group | Buy | $15 |
| 2014-09-18 | Reiterated | WBB Securities | Strong Buy | $27 |
| 2014-01-02 | Reiterated | Aegis Capital | Buy | $21 to $23 |
| 2013-09-12 | Initiated | MLV & Co | Buy | $16 |
| 2013-06-24 | Initiated | Aegis Capital | Buy | $2.50 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In NBS 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| RimAsia Capital Partners Manager, Ltd. | 6.31% (2222988) | NBS / |
| RimAsia Capital Partners, L.P. | 6.27% (2210988) | NBS / |
| Pecora Andrew L Chief Medical Officer | 1.12% (393784) | CGIX / NBS / TLOG / |
| Smith Robin L Chairman of the Board and CEO | 0.99% (347285) | NBS / RMTI / SGNL / |
| VATERS ROBERT S President & CFO | 0.65% (228750) | NBS / |
| Wei Eric | 0.49% (172223) | NBS / |
| Mazzo David J Chief Executive Officer | 0.27% (96706) | AVNR / NBS / PSDV / RGDO / |
| LOSORDO DOUGLAS W Chief Medical Officer | 0.25% (88892) | NBS / |
| GREENACRE MARTYN D | 0.25% (88531) | CRIS / NBS / |
| VACZY CATHERINE M VP and General Counsel | 0.20% (71234) | NBS / |
| MYERS STEVEN S | 0.10% (36159) | NBS / |
| Preti Robert A See Remarks | 0.10% (33786) | NBS / |
| Talamo Joseph See Remarks | 0.09% (30120) | NBS / |
| Potter Stephen W | 0.04% (14016) | AGTC / NBS / OSIR / |
| Dickey Robert IV Chief Financial Officer | 0.03% (12066) | HEB / NBS / |
| BERNSTEIN DREW | 0.03% (10000) | NBS / |
| KLOSK STEVEN M | 0.03% (9065) | CBM / NBS / |
| BERMAN RICHARD J | 0.02% (7177) | ADXS / APRI / NBS / |
| TRABER PETER G | 0.02% (6865) | GALT / NBS / |
| BROWN GREGORY B | 0.02% (6715) | CBM / NBS / |
UM